Using a mouse hepatoma model, PD-1 therapy delays tumor growth by recovering CD8+ T cell infiltration and function in a TI PD-1+ B cell-dependent manner (Xiao et al., 2016) (Table 2). Here, PDCD1 is linked to hepatocellular carcinoma.